AA
AARD

ALPS Advisors’s Aardvark Therapeutics AARD Stock Holding History

ALPS Advisors’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$66.8K Sell
17,727
-150
-0.8% -$1.55K ﹤0.01% 1035
2025
Q4 		$235K Buy
+17,877
New +$223K ﹤0.01% 957

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

ALPS Advisors's AARD Position: Q1 2026 in Review

ALPS Advisors reduced its Aardvark Therapeutics (AARD) stake by 0.84% in Q1 2026, selling an estimated $1.55K and leaving 17,727 shares worth $66.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1035.

ALPS Advisors first reported a position in AARD in Q4 2025 and has held it in 2 quarters since. The position peaked at $235K in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • ALPS Advisors held 17,727 shares of Aardvark Therapeutics worth $66.8K as of Q1 2026.
  • ALPS Advisors sold 150 Aardvark Therapeutics shares in Q1 2026, an estimated $1.55K.
  • Aardvark Therapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q1 2026, its #1035 holding.
  • ALPS Advisors first reported a position in Aardvark Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • ALPS Advisors's Aardvark Therapeutics position peaked at $235K in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.